ARA:NYE-American Renal Associates Holdings, Inc (USD)

COMMON STOCK | Diagnostics & Research | NYE

Last Closing Price

USD 11.44

Change

0.00 (0.00)%

Market Cap

USD 0.39B

Volume

0.35M

Average Target Price

USD 8.00 (-30.07%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-26 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TMO Thermo Fisher Scientific Inc

N/A

USD177.74B 36.97 23.40
DHR Danaher Corporation

N/A

USD154.31B 54.83 32.41
DHR-PA Danaher Corporation

N/A

USD137.34B 247.45 N/A
PHG Koninklijke Philips N.V

N/A

USD45.95B 34.95 33.79
A Agilent Technologies, Inc

N/A

USD35.26B 49.95 29.84
IQV IQVIA Holdings Inc

N/A

USD32.57B 187.43 22.45
MTD Mettler-Toledo International I..

N/A

USD26.77B 48.38 33.59
LH Laboratory Corporation of Amer..

N/A

USD19.14B 23.06 12.15
DGX Quest Diagnostics Incorporated

N/A

USD16.76B 15.14 10.21
PKI PerkinElmer, Inc

N/A

USD14.28B 35.80 20.70

ETFs Containing ARA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.32% 42% F 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.32% 42% F 74% C
Trailing 12 Months  
Capital Gain 23.28% 58% F 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.28% 58% F 83% B
Trailing 5 Years  
Capital Gain -46.16% 13% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.16% 13% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain -19.01% N/A N/A 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.01% N/A N/A 5% F
Risk Return Profile  
Volatility (Standard Deviation) 28.78% N/A N/A 22% F
Risk Adjusted Return -66.07% N/A N/A 6% F
Market Capitalization 0.39B 21% F 40% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 154.10 19% F 4% F
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio 10.17 74% C 39% F
EV/EBITDA 9.34 100% A+ 67% D+
Management Effectiveness  
Return on Equity 17.51% 82% B- 86% B
Return on Invested Capital 13.88% 89% B+ 83% B
Return on Assets 4.40% 47% F 76% C
Debt to Equity Ratio -681.00% 94% A 98% A+
Technical Ratios  
Short Ratio 4.86 28% F 20% F
Short Percent 3.34% 35% F 57% F
Beta 1.23 26% F 37% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.